Juan Sepúlveda
Hospital Universitario 12 de Octubre · Hospital 12 de Octubre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Juan Sepúlveda as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:55 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05635734 · Azeliragon and Chemoradiotherapy in Newly Diagnosed GlioblastomaCantex Pharmaceuticals · completed · Glioblastoma · study chair
- Ph2NCT01520870 · Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.Grupo Español de Investigación en Neurooncología · completed · Glioblastoma, Brain Tumor, Recurrent · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:55 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.JAMA Oncol · 20201,288 citationsRCR 55.9
- 482 citationsRCR 43.2
- INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.Neuro Oncol · 2020163 citationsRCR 7.4
- Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.Neuro Oncol · 202451 citationsRCR 6.9
- Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.J Neurooncol · 201648 citationsRCR 1.7
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.J Neurooncol · 202045 citationsRCR 2.0
- 35 citationsRCR 1.4
- A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.Clin Transl Oncol · 201513 citationsRCR 0.4
- 4 citationsRCR 0.7
- Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial.Nat Commun · 20253 citationsRCR 0.7